Type II secretory phospholipase A2 and prognosis in patients with stable coronary heart disease: mendelian randomization study |
| |
Authors: | Breitling Lutz P Koenig Wolfgang Fischer Marcus Mallat Ziad Hengstenberg Christian Rothenbacher Dietrich Brenner Hermann |
| |
Institution: | Division C070 Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. l.breitling@fkfz-heidelberg.de |
| |
Abstract: | BackgroundSerum type II secretory phospholipase A2 (sPLA2-IIa) has been found to be predictive of adverse outcomes in patients with stable coronary heart disease. Compounds targeting sPLA2-IIa are already under development. This study investigated if an association of sPLA2-IIa with secondary cardiovascular disease (CVD) events may be of causal nature or mainly a matter of confounding by correlated cardiovascular risk markers.Methodology/Principal FindingsEight-year follow-up data of a prospective cohort study (KAROLA) of patients who underwent in-patient rehabilitation after an acute cardiovascular event were analysed. Associations of polymorphisms (SNP) in the sPLA2-IIa-coding gene PLA2G2A with serum sPLA2-IIa and secondary fatal or non-fatal CVD events were examined by multiple regression. Hazard ratios (HR) were compared with those expected if the association between sPLA2-IIa and CVD were causal. The strongest determinants of sPLA2-IIa (rs4744 and rs10732279) were associated with an increase of serum concentrations by 81% and 73% per variant allele. HRs (95% confidence intervals) estimating the associations of the SNPs with secondary CVD events were increased, but not statistically significant (1.16 0.89–1.51] and 1.18 0.91–1.52] per variant allele, respectively). However, these estimates were very similar to those expected when assuming causality (1.18 and 1.17), based on an association of natural log-transformed sPLA2-IIa concentration with secondary events with HR = 1.33 per unit.ConclusionThe present findings regarding genetic polymorphisms, determination of serum sPLA2-IIa, and prognosis in CVD patients are consistent with a genuine causal relationship and thus might point to a valid drug target for prevention of secondary CVD events. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|